Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $140.00

Kymera Therapeutics (NASDAQ:KYMR) had its price target hoisted by Piper Sandler from $125.00 to $140.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Piper Sandler’s target price points to a potential upside of 56.75% from the company’s previous close.

A number of other research firms have also issued reports on KYMR. Morgan Stanley upped their target price on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the stock an “overweight” rating in a report on Tuesday, December 9th. JPMorgan Chase & Co. boosted their price target on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. HC Wainwright boosted their target price on Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Guggenheim began coverage on shares of Kymera Therapeutics in a report on Monday, November 3rd. They issued a “buy” rating and a $90.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Buy” and an average price target of $117.75.

Kymera Therapeutics Stock Performance

Shares of KYMR traded down $1.37 during trading hours on Thursday, hitting $89.31. The stock had a trading volume of 442,750 shares, compared to its average volume of 761,862. The firm has a 50-day moving average price of $78.07 and a 200 day moving average price of $64.68. Kymera Therapeutics has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The firm has a market capitalization of $6.43 billion, a price-to-earnings ratio of -24.98 and a beta of 2.21.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The business had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The firm’s revenue for the quarter was down 60.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.88) earnings per share. As a group, analysts predict that Kymera Therapeutics will post -2.79 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $90.26, for a total transaction of $2,707,800.00. Following the transaction, the chief executive officer owned 666,195 shares of the company’s stock, valued at $60,130,760.70. This trade represents a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bruce Booth sold 678 shares of the business’s stock in a transaction dated Friday, December 12th. The shares were sold at an average price of $91.04, for a total value of $61,725.12. Following the completion of the transaction, the director owned 685,393 shares in the company, valued at $62,398,178.72. This trade represents a 0.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 450,895 shares of company stock valued at $40,486,151. 16.01% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. US Bancorp DE increased its holdings in Kymera Therapeutics by 9.8% in the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after buying an additional 166 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Kymera Therapeutics by 9.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after acquiring an additional 248 shares during the period. Larson Financial Group LLC raised its holdings in Kymera Therapeutics by 36.9% during the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after purchasing an additional 287 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its position in Kymera Therapeutics by 3.3% during the fourth quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company’s stock worth $985,000 after purchasing an additional 410 shares in the last quarter. Finally, Smartleaf Asset Management LLC grew its holdings in Kymera Therapeutics by 382.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock valued at $42,000 after purchasing an additional 424 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.